The NIH funds network to study drug-induced liver injury (DILIN)

November 19, 2004

The National Institutes of Health (NIH) has launched a network of five clinical centers and a data coordinating center to conduct studies over the next three years of patients who have suffered severe liver injury because of both prescription and "over-the-counter medications," nutritional supplements, alternative medicines and herbals. The DILIN centers are located in North Carolina, Indiana, San Francisco, Michigan, and Connecticut, and will be awarded $2.25 million per year.

One objective of DILIN is to develop standardized definitions and instruments to identify and fully characterize cases of drug-induced liver injury. With a systematic way of classifying drug-induced liver injury, researchers will be able to analyze the epidemiology and clinical issues of liver injury and collect biological samples that can be used to study the causes of liver toxicity using biochemical, serological, and genetic testing. The DILIN is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), one of the institutes of the NIH.

Another objective of DILIN is to establish a registry of patients who have experienced severe drug induced liver injury. "Part of the difficulty in studying drug-induced liver disease is the absence of a sufficient cohort of well-characterized patients in whom to carry out clinical, genetic, immunological and biochemical investigation," says Jose Serrano, M.D., Ph.D, director, NIDDKs' Liver and Biliary Diseases Program and coordinator of the DILIN. "DILIN will help to eliminate this barrier and advance the understanding of drug-induced liver injury forward," he adds.

Drug-induced liver injury occurs in all age groups, but most cases occur within the elderly population because they take more medications than younger persons and also use multiple medications. Furthermore, drug-induced liver injury is the most common reason why drugs are not approved by the Food and Drug Administration (FDA) or are removed from the market after they have been approved.

Most drugs that can cause liver injury are entirely safe for the majority of patients taking them. The reason why some patients are susceptible to liver injury from a drug is rarely known. "It is likely a result of many interrelated factors that involve complex interactions between our genes and the environment," says Jay Hoofnagle, M.D., director, NIDDK Liver Diseases Research Branch. "Liver injury is unpredictable and variable in clinical presentation, making causality very tough to assess," explains Hoofnagle.

At present, DILIN has developed protocols for both retrospective and prospective studies of drug-induced liver disease. The retrospective study will establish a registry of patients who have taken one of four specific drugs since 1994 and developed liver injury later.

The four drugs are isoniazid, phenytoin, valproic acid, and clavulanic acid/amoxicillin. These drugs were chosen because they are widely prescribed and have definite clinical presentation. A minimum of 50 cases of each form of drug-induced liver disease will be collected along with an equal number of patients who have taken the drugs safely (controls). The researchers will obtain clinical and DNA information from each patient.

The prospective study will focus on enrolling patients who recently suffered an adverse liver reaction after taking any drug or herbal medicine. These patients will be followed over time to find out what happens to them as a result of their injury. Patients who have not sustained liver injury, but who have taken any of the drugs in question, will also be enrolled in the prospective study.

"Overall, we believe that the DILIN will bring greater focus and interest to the study of drug-induced liver injury and help to develop better ways to prevent, detect, and treat this growing liver problem," says Paul Watkins, M.D., chair, the DILIN Steering Committee and principal investigator for the center in North Carolina. The DILIN researchers have also developed diagnostic criteria and measures for grading causality in patients with drug-induced liver disease and will prospectively assess these instruments for sensitivity and specificity. Patient enrollment is ongoing.

The DILIN consists of the following principal investigators and centers:
For more information, contact Leslie Curtis or Marcia Vital at the NIDDK Information Office (301-496-3583).

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is a component of the National Institutes of Health (NIH), U.S. Department of Health and Human Services (DHHS). NIDDK supports a significant amount of the Federal Government's research on endocrine and metabolic diseases such as diabetes and obesity, digestive diseases such as hepatitis and inflammatory bowel disease, kidney and urologic diseases such as kidney failure and prostate enlargement, and blood diseases such as the anemias. The Institute carries out a large variety of research initiatives and programs that will bring new knowledge into proven therapies that benefit the public. Health information and additional information about NIDDK can be found on the NIDDK home page at:

NIH/National Institute of Diabetes and Digestive and Kidney Diseases

Related Liver Injury Articles from Brightsurf:

Eating less suppresses liver cancer due to fatty liver
Liver cancer from too much fat accumulation in the liver has been increasing in many countries including Japan.

Study shows proof of concept of BioIVT HEPATOPAC cultures with targeted assay to evaluate bioactivation potential and drug-induced liver injury (DILI) risk
New in vitro Bioactivation Liver Response Assay used HEPATOPAC model to demonstrate utility of in vitro transcriptomic signature-based strategy in preclinical DILI risk assessment.

Gene test can predict risk of medications causing liver injury
A team of scientists from Cincinnati Children's, Japan and Europe report in a study published Sept.

UTHealth's Cynthia Ju awarded NIH grants for liver injury research
Tiny solutions are being sought for big liver problems by a scientist at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth).

Longevity protein SIRT6 also protects against fatty liver and fatty liver disease
SIRT6 regulates fat metabolism by activating another protein called peroxisome proliferator-activated receptor alpha (PPAR-alpha).

Lactobacillus balances gut microbiome and improves chronic-alcohol-induced liver injury
Researchers demonstrated that Lactobacillus rhamnosus can dose-dependently reestablish a balanced intestinal microbiome and counter the liver-damaging effects of alcohol consumption in mice to reverse the results of chronic alcohol-induced liver injury.

Immune cell identity crisis: What makes a liver macrophage a liver macrophage?
UC San Diego researchers investigated how a type of immune cell called a macrophage becomes specialized to the liver.

Liver transplants could be redundant with discovery of new liver cell
Researchers at King's College London have used single cell RNA sequencing to identify a type of cell that may be able to regenerate liver tissue, treating liver failure without the need for transplants.

New insights on liver injury in men taking body building supplements
In a study reported in Alimentary Pharmacology & Therapeutics, 44 men with liver injury, attributed to over-the-counter bodybuilding supplements, experienced a uniform and distinctive pattern of signs and symptoms that were often prolonged, difficult to treat, and accompanied by disability and weight loss.

Blocking platelets: A possible option to prevent fatty liver disease and liver cancer
Blood platelets which interact with liver cells and immune cells play a major role in the development of fatty liver disease, non-alcoholic fatty liver inflammation and liver cancer, scientists from the German Cancer Research Center (DKFZ) in Heidelberg and from Zurich University and University Hospital have now shown in a publication.

Read More: Liver Injury News and Liver Injury Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to